Home About Us Services Therapies Blogs Contact Us Call: +91 6567383855

Start typing to search products or segments…

Home / Diabetology / Dapabet-M-1000-XR

Back to Diabetology
Diabetology

Dapabet-M-1000-XR

TabletsPacking : 10 x10 Alu

Composition- Dapagliflozin 10mg+Metformin 1,000mg

MRP : 1500/-

Share :
Prescribed By : Diabetologists | Endocrinologists | Consultant Physicians | Internal Medicine Specialists | General Physicians

Product Description

Key Benefits of Dapabet-M-1000-XR

  • Combines two complementary mechanisms to provide effective control of fasting and postprandial blood glucose levels.
  • Supports sustained improvement in long-term glycaemic control in adults with Type 2 Diabetes Mellitus.
  • Metformin improves insulin sensitivity and reduces excessive hepatic glucose production.
  • Dapagliflozin promotes urinary glucose excretion and may support modest body-weight reduction alongside diet and exercise.
  • Provides glucose-lowering action with a low inherent risk of hypoglycaemia when used without insulin or sulfonylureas.

Indications of Dapabet-M-1000-XR

  • Type 2 Diabetes Mellitus inadequately controlled with metformin alone
  • Type 2 Diabetes Mellitus requiring dual oral antidiabetic therapy
  • Patients with inadequate glycaemic control despite diet and exercise
  • Overweight or obese adults with Type 2 Diabetes Mellitus requiring improved glycaemic management

How Dapabet-M-1000-XR works

Dapagliflozin selectively inhibits Sodium-Glucose Co-Transporter 2, or SGLT2, in the kidneys. This reduces renal glucose reabsorption and increases the elimination of excess glucose through urine. Metformin decreases hepatic glucose production, reduces intestinal glucose absorption and improves peripheral insulin sensitivity. Together, they deliver complementary, insulin-independent and insulin-sensitising actions for comprehensive glycaemic control.

Why ChooseDapabet-M-1000-XR?

Complementary dual mechanism of action Effective control of fasting and post-meal glucose Helps achieve and maintain target HbA1c levels Supports weight-conscious diabetes management Convenient fixed-dose combination therapy Low intrinsic potential for hypoglycaemia Suitable for patients inadequately controlled on metformin alone

Last updated on 26 July 2026

This information is for reference only and is not a substitute for advice from a qualified doctor or pharmacist. Please consult your physician before use.

Want to partner with Cista Medicorp?

Reach out to our team for distribution, bulk orders or enquiries.

WhatsApp Now
Link copied — paste it in Instagram
Chat with us